Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant.
Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients).
The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial.
Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.
